The ExoDx Prostate Test is a non-invasive, non-digital rectal exam, urine test used as a risk assessment tool to provide risk probabilities for aggressive prostate cancer. The technology relies on cancer-specific genomic biomarkers found in the urine. The test analyzes three cancer-specific biomarkers found in the urine associated with aggressive prostate cancer: ERG, PCA and more »
Two recent approvals by the Food and Drug Administration (FDA) have opened a new avenue of treatment for some men with prostate cancer: an expanded role for targeted therapies. The approvals are for the drugs olaparib (Lynparza) and rucaparib (Rubraca). They cover the use of the drugs in men whose prostate cancer has spread, or more »
The American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) have released new guidelines for the diagnosis and treatment of advanced prostate cancer, developed by a panel of experts. In addition to their own expertise and experience, panel members assessed data from 264 prostate cancer studies in developing more »
In this third video of the PCRI series, Dr. Mark Scholz discusses the role of diet as related to prostate cancer. His overwriting principal is vegetarianism, avoiding animal products. Dr. Scholz bases his conclusion on his observation of patients who lowered their PSA levels while on strict vegan diets. Dr. Scholz also discusses the fact more »
Dr. Mark Scholz, Executive Director of the PCRI, has generated an eight minute video discussing the major issues related to bone metastasis. Bone metastases generally occur in a small percentage of men and can appear 10-20 years after continuous prostate cancer treatment. Bone mets can be observed when the PSA levels exceed 20-30 or hundreds. more »
Dr. Mark Scholz, Executive Director of the Prostate Cancer Research Institute (PCRI), has produced three very informative short videos dealing with topics such as 1) active surveillance (AS) for men recently diagnosed with prostate cancer, 2) bone metastasis and, 3) diet and cancer. This first 7 minute AS video defines the terms “watchful waiting” as more »
Using a comprehensive analysis of all the genetic risk data concerning prostate cancer for African American men, Dr. Chris Haiman of the University of Southern California and his team of over 200 researchers were able to determine that it was possible to create an affordable test, based solely on a man’s saliva or blood sample, more »
The annual Prostate Cancer Research Institute (PCRI) Conference is a comprehensive educational experience for prostate cancer patients and caregivers. The conference moderated by Mark Moyad, MD, consists of keynote presentations from leading doctors followed by live question – and – answer sessions. Keynote topics include all treatments, newly-diagnosed, diet and exercise, sexual dysfunction, active surveillance, more »
This morning I experienced a brief but annoying episode of a recurrent medical issue and potentially a new one. My initial reaction was tension mixed with a little “worry” and “what if”. I have been down that same road before. Almost immediately, God’s Word from James 1:6-7 came to me. “For the one who doubts more »
Data from more than 6,000 Medicare patients showed that adding the immunotherapy Provenge (sipuleucel-T) to a regimen containing the oral agents Zytiga (abiraterone acetate) or Xtandi (enzalutamide) significantly extended the lives of men with metastatic hormone-resistant prostate cancer (mCRPC). The findings were presented in a poster at the recent American Society of Clinical Oncology (ASCO) more »
Several years ago, I experienced an annoying side effect which had arisen related to earlier prostate cancer therapy. The side effect had been “cured” by a specific series of treatments but now it had reared its troublesome head again. One recent Sunday, it was especially troublesome. There are potential treatments for this condition but my more »
This post is very personal to me and provided me with encouragement at this time of personal need. While I am currently asymptomatic, for which I am immensely grateful, I know I have metastatic sites of prostate cancer in my body. Upon a recent visit to my oncologist, he calmly but coldly and clinically told more »
This website usually focuses exclusively on prostate cancer but this particular post could apply to the current worldwide coronavirus pandemic as well. Right now we as a nation and many of us as individuals may have a potential medical problem that has our stomach in knots with persistent worry. For most of us, it is more »
Upon recent discussions with my urologist and oncologist, they both informed me that the following is a highly significant development in imaging of prostate cancer. A medical imaging technique, known as PSMA PET/CT, that provides detailed body scans while detecting levels of a molecule associated with prostate cancer could help doctors better tailor treatments for more »
The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration (hormone)-resistant prostate cancer (mCRPC) and BRCA mutations. Clovis submitted its application to the FDA in November, 2019. The priority review status will shorten Rubraca’s regulatory review for this more »
How do you react in a severe storm or if you receive bad news? Do you tense up with fear or do you recall words such as those in Psalm 107:28-30? “Then they cry out to the Lord in their trouble, and He brings them out of their distresses. He calms the storm, so that more »
The National Cancer Institute (NCI) is sponsoring a clinical trial at many locations comparing two types of radiation therapy, stereotactic body radiation therapy (SBRT) with intensity-modulated radiation therapy (IMRT). The former is administered in less than two weeks while the latter is given in five weeks. The aim of the trial is to compare cure more »
Tumor samples from a prostate biopsy are graded (Gleason score) which is an indication of a tumor’s aggressiveness. The tumor grade reflects how far the cancer cells deviate from normal healthy cells. Gleason 6 cancer looks almost like normal prostate gland tissue while higher Gleason scores are indicative of more serious cancers. The Prostate Cancer more »
Blogger Dr. Bjarne (B.J.) Gabrielsen at Boca Grande Lighthouse, Charlotte Harbor, Punta Gorda, Southwest Florida Gulf Coast I am a prostate cancer survivor since 1995. If you know of any men in your life who may have an interest in prostate cancer at any stage of disease, please inform them of this website, Godandprostate.net, .com, more »
Every year, the PCF publishes an electronic guide providing information on all aspects of prostate cancer. The chapters covered are as follows. General information including diagnosis, symptoms, risk factors, and medical basics. Information for the newly diagnosed, including detection, diagnosis and treatment selection. Treatment options for localized or locally advanced prostate cancer. These include active more »